Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales

Intuitive Surgical’s Q3 2026 adjusted EPS rose 25% to $3.00, beating estimates by 13.6%, while revenue increased 21.7% to $3.05B and exceeded expectations by about 4.9%. System revenue grew 30.3% to $769.1M on 546 da Vinci placements; adjusted gross margin expanded to 69.9%, though it was 68.9% excluding a $28M tariff refund. The company narrowed 2026 da Vinci procedure growth guidance to 14–15% and raised its adjusted gross margin outlook to 68.7–69.3%; GAAP net income fell to $523M, including a $450M pretax antitrust settlement charge, and it repurchased $2.94B of shares.

Analysis

The beat is higher quality than the headline suggests in one respect and less incremental in another: excluding the tariff refund, gross-margin expansion still points to underlying efficiency, but the narrowed procedure-growth range leaves its midpoint unchanged. Treat the quarter as execution confirmation, not a clear acceleration signal. The more consequential debate is whether planned 2027 instrument price cuts buy enough incremental procedures to offset lower revenue per case. Because instruments and accessories are recurring, a 3–5% revenue-per-procedure drag can compound across the installed base; the bull case requires procedure growth and mix to compensate, not simply more placements. Track procedure growth against revenue per procedure and the pace of da Vinci 5 utilization.

For the next 1–3 months, placements and procedure trends support the growth narrative, while the litigation charge makes GAAP earnings a noisy read-through. Over 6–18 months, China policy and pricing changes are the key margin/revenue test. The $28 million tariff refund should not be annualized; persistent margin progress depends on operating efficiencies. Repurchases may support per-share results, but the cash decline reduces flexibility and makes sustained buyback capacity worth monitoring. Globus Medical is a relevant adjacent surgical-robotics competitor, but this quarter alone does not establish share loss or gain; Glaukos is not a direct read-through to da Vinci demand. Contrarian point: strong placements can mask weaker economics per procedure, and the guidance midpoint did not rise. Falsify the cautious view if procedure growth consistently offsets falling revenue per procedure while ex-refund gross margin holds or expands.

Key Decisions for Investors

• Avoid chasing the earnings beat on fundamentals alone. Consider initiating or adding ISRG on post-event weakness, contingent on procedure growth holding near the company’s outlook and ex-refund gross margin remaining firm; reduce exposure if procedure growth slips below the outlook or revenue per procedure falls faster than pricing guidance implies.
• Set a 2027 pricing watch: quarterly instrument revenue per procedure, procedure growth, and management commentary on adoption in targeted benign procedures. The thesis is volume elasticity; absent evidence that incremental cases offset lower pricing, treat the cuts as a recurring-revenue headwind rather than an automatic access-driven positive.
• Do not infer a negative read-through to GMED from this report. Monitor Globus Medical separately for robotics-related demand and competitive commentary before expressing a relative-value position.
• Monitor cash, repurchases, and litigation developments; a sustained reduction in cash alongside continued large buybacks, or further material legal charges, would weaken the capital-return and earnings-quality case.